摘要
目的测定急性冠状动脉综合征(ACS)患者应用不同剂量阿托伐他汀后血浆B型钠尿肽(BNP)及超敏C反应蛋白(hsCRP)水平的变化,探讨ACS患者住院早期应用阿托伐他汀的临床意义及最佳剂量。方法选择ACS患者78例,随机分为3组:阿托伐他汀10mg组28例,阿托伐他汀20mg组28例,阿托伐他汀40mg组22例,均于入院24小时内开始给予阿托伐他汀治疗,测定3组入院时及治疗5天后血浆BNP及hsCRP水平的变化。结果 ACS患者早期应用阿托伐他汀可明显降低血浆BNP及hsCRP水平,阿托伐他汀20mg组及阿托伐他汀40mg组均优于阿托伐他汀10mg组,BNP(543±116)ng/L,(531±112)ng/L vs(738±121)ng/L(P<0.01);hsCRP(7.02±3.17)mg/L,(6.87±3.21)mg/L vs(9.32±3.43)mg/L(P<0.01),阿托伐他汀40mg组优于阿托伐他汀20mg组,但差异无统计学意义(P>0.05)。结论 ACS患者早期应用阿托伐他汀可降低血浆BNP及hsCRP水平,阿托伐他汀40mg、20mg作用明显优于10mg。
Objective To investigate the effect of early intervention by atorvastatin with different dosage on plasma level of B-type natriuretic peptide（BNP） and high sensitive C-reactive protein（hsCRP） in patients with acute coronary syndrome （ACS）. Methods Seventy-eight patients with ACS were divided randomly into three groups： atorvastatin group 10 mg （n = 28）,atorvastatin group 20 mg（ n = 28）, atorvastatin group 40 mg （n = 22）. All patients took atorvastatin in 24 hours after admission. Blood samples were examined for BNP and hsCRP level at admission and five days after the therapy of atorvastatin in three groups of patients. Results The use of atorvastatin in early admission period of ACS significantly reduced plasma BNP and hsCRP level, the effect which was more obvious in atorvastatin group 20 mg/d and atorvastatin group 40 mg/d than in atorvastatin group 10 mg/d, （543±116） ng/L, （531±12） ng/L vs （738±121） ng/L;（7.02±3.17） mg/L,（6.87±3.21） mg/L vs （9.32±3.43） mg/L（P 〈 0.01）. The effect of atorvastatin group 40 mg/d was superior to that of atorvastatin group 20 rag/d, but there was no significant difference between them （ P 〉 0.05）. Conclusion The early use of atorvastatin in ACS patients reduces serum BNP and hsCRP level,atorvastatin 40 mg,20 mg/d are better than 10 mg/d.
出处
《临床荟萃》
CAS
2012年第13期1123-1125,共3页
Clinical Focus
